Tovorafenib (TAK-580, MLN-2480) is an orally bioavailable oxindole that selectively inhibits pan–rapidly accelerated fibrosarcoma (A-RAF, B-RAF, C-RAF) serine/threonine kinases, blocking mitogen-activated protein kinase signaling in glioma models.
Usually ships within 24 hours.